Imaging Multiparametric/Multimodality for Lungcancer (IRMomics)

Assistance Publique - Hôpitaux de Paris

Status

Unknown

Conditions

Lungcancer

Treatments

Other: Magnetic Resonance Imaging (MRI)

Study type

Interventional

Funder types

Other

Industry

Identifiers

ANSM (Other Identifier)

K160701

Details and patient eligibility

About

To build an imaging biobank of 200 patients with lungcancer, including pathologic and molecular characteristics of the tumor (mutational status, circulating DeoxyriboNucleic Acid (DNA) from serum biobank...), staging of the cancer (according to the new 2016 Tumor Node Metastasis (TNM) status, the table that classify non-small cell lungcancer) and follow-up informations (Response to first-line treatment (Response Evaluation Criteria in Solid Tumors (RECIST)), disease-free survival, 1-3 years survival).
To propose a simple severity scoring system based on tumor features such as size, doubling time (if available), location, amount of enhancement and necrosis. Such approach has been proposed for glioma evaluation (Visually Accessible Rembrandt Images (VASARI)) but is not available for the lung. The objective is to do better than the Tumor Node Metastasis (TNM) staging.
To develop and evaluate an IntraVoxel Incoherent Motion (IVIM) protocol for lungcancer evaluation.

Enrollment

200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adults over 18 years
High suspicion of lungcancer confirmed
Tumor > 2 cm
Incomplete cerebral staging or not yet realized in the initial consultation of screening

Exclusion criteria

Lungcancer medical history
During Pregnancy
Contraindications to MRI
Patient not able to understand the information of the protocol, taking into account the state of the brain
Patient unable to keep lying in MRI the necessary time